Last updated: September 26, 2026
Lo Loestrin Fe is a branded low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol. AbbVie owns the U.S. commercial business following its 2020 acquisition of Allergan, which acquired the product through Warner Chilcott. The product remains commercially differentiated by its ultra-low 10-microgram ethinyl estradiol dose, 24 active tablets, and four ferrous fumarate tablets.
Its financial profile is driven by brand pricing, physician familiarity, formulary access, and delayed generic substitution. AbbVie does not currently report Lo Loestrin Fe as a separate revenue line, so recent product-level sales and margins cannot be verified from public filings. The principal long-term risk is generic entry into the norethindrone acetate/ethinyl estradiol market, while the principal commercial support is the product's established position in the low-dose oral contraceptive segment.
What is Lo Loestrin Fe and how does it compete?
Lo Loestrin Fe is a combined oral contraceptive approved by the FDA in 2010. Each 28-day pack contains:
| Component |
Quantity |
| Norethindrone acetate |
1 mg in active tablets |
| Ethinyl estradiol |
10 mcg in the first 24 active tablets |
| Ferrous fumarate |
Included in four non-hormonal tablets |
The product is indicated for the prevention of pregnancy in women who elect to use an oral contraceptive. Its 10-microgram ethinyl estradiol dose is lower than the estrogen dose used in many competing combined oral contraceptives. The product label warns that lower-estrogen formulations can be associated with more unscheduled bleeding and spotting, particularly during initial treatment cycles. [1]
How does Lo Loestrin Fe compare with competing contraceptives?
| Product or category |
Estrogen profile |
Commercial position |
Principal competitive issue |
| Lo Loestrin Fe |
10 mcg ethinyl estradiol |
Premium branded ultra-low-dose product |
Brand price and generic substitution |
| Loestrin 24 Fe generics |
Generally 20 mcg ethinyl estradiol |
Low-cost generic alternatives |
Different estrogen dose and formulation |
| Junel Fe and related generics |
Commonly 20 mcg ethinyl estradiol |
Broad generic access |
Formulary preference and price |
| Yaz and generic drospirenone products |
20 mcg ethinyl estradiol |
Differentiated by progestin |
Different safety and tolerability profile |
| Nextstellis |
Estetrol plus drospirenone |
Newer branded option |
Limited commercial maturity and premium pricing |
| Progestin-only pills |
No estrogen |
Alternative for patients with estrogen restrictions |
Different bleeding and adherence profile |
Lo Loestrin Fe competes on dose design and brand recognition rather than on a unique mechanism. The product does not have the exclusivity characteristics of a biologic or specialty drug.
What is the FDA regulatory status of Lo Loestrin Fe?
Lo Loestrin Fe is an FDA-approved prescription drug marketed under NDA 021871. It is a small-molecule combination product, not a biologic. The FDA-approved dosage form is an oral tablet supplied in a 28-day regimen. [1]
The regulatory record includes the original approval, labeling updates, and postmarketing safety information applicable to combined hormonal contraceptives. The key regulatory risks are typical of estrogen-containing contraceptives:
- Venous and arterial thrombotic events
- Cardiovascular risk in smokers, especially women over age 35
- Hypertension
- Liver disease
- Drug interactions that reduce contraceptive efficacy
- Abnormal bleeding and discontinuation
The FDA has not classified Lo Loestrin Fe as a biologic, so biosimilar competition is not relevant. Any follow-on competition proceeds through the abbreviated new drug application, or ANDA, pathway for small-molecule generics.
What patents protect Lo Loestrin Fe?
Lo Loestrin Fe's protection has historically depended on formulation, composition, and product-specific patent listings rather than on a single broad platform patent. The relevant legal sources are the FDA Orange Book, issued U.S. patents, patent-term-adjustment records, and any Paragraph IV litigation filed against ANDA applicants. [2]
A current patent assessment should distinguish among:
- Patents listed for the finished drug product in the Orange Book.
- Patents covering the hormone combination or dosage regimen.
- Patents covering packaging or administration.
- Unlisted process or manufacturing patents.
- Regulatory exclusivity, which is separate from patent protection.
The FDA's public Orange Book identifies patents submitted by the NDA holder and patent certifications associated with ANDA applications. Orange Book listings do not establish that every listed patent will survive litigation or block commercial entry through its full expiration date. [2]
What formulations are protected by Lo Loestrin Fe patents?
The commercially important formulation characteristics include:
- A 10-microgram ethinyl estradiol active tablet.
- Norethindrone acetate as the progestin.
- A 24-day active-pill regimen.
- Four ferrous fumarate tablets in each pack.
- A specific tablet sequence and packaging configuration.
Formulation patents can impose a higher development burden than a conventional generic tablet because an ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence for the relevant active and non-active components. That burden does not necessarily prevent generic entry. It can increase development time, manufacturing complexity, and litigation cost.
What is the Orange Book status of Lo Loestrin Fe?
Lo Loestrin Fe remains an FDA-listed prescription product. The live Orange Book record, including current patent listings and ANDA certifications, is the controlling source for market exclusivity analysis. FDA Orange Book records should be read together with the product's NDA history because listed patents may cover different strengths, formulations, or product presentations. [2]
No biosimilar pathway applies. The central competitive question is whether an ANDA applicant has received final approval and whether listed patents, court orders, or settlement terms delay launch.
When does Lo Loestrin Fe lose exclusivity?
Lo Loestrin Fe's regulatory exclusivity has expired. Its commercial protection therefore depends primarily on patent status, brand demand, contracting, and the timing of generic approvals.
The product was approved in 2010. Standard five-year new chemical entity exclusivity is not the primary current barrier because the product has been marketed for more than a decade. Pediatric exclusivity, if granted for a particular FDA action, would add six months to applicable exclusivity but would not create a current long-term barrier for the product. [2]
Patent expiration analysis requires the following distinctions:
| Protection type |
Relevance to Lo Loestrin Fe |
| New chemical entity exclusivity |
Expired or no longer commercially controlling |
| Five-year exclusivity |
Expired |
| Three-year clinical-investigation exclusivity |
Not the principal current barrier |
| Pediatric exclusivity |
Time-limited and not a current long-term defense |
| Orange Book patents |
Potentially relevant to ANDA launch timing |
| Manufacturing patents |
May create technical barriers but may not block all ANDA products |
| Trademark and trade dress |
Protect branding, not the active ingredient |
The highest-value commercial date is not necessarily the latest patent expiration date. A generic company may launch “at risk” after patent litigation, enter under a settlement, or launch after a court judgment invalidates or narrows the asserted claims.
Which companies are challenging Lo Loestrin Fe?
Publicly available market information indicates that Lo Loestrin Fe is exposed to the same generic competition that affects other norethindrone acetate/ethinyl estradiol oral contraceptives. The relevant potential challengers are manufacturers with ANDA portfolios in oral contraceptives, including large generic companies and specialty generic manufacturers.
A definitive challenger list requires current FDA ANDA records and federal court dockets. The relevant events are:
- Paragraph IV certification against an Orange Book-listed patent.
- Notice of Paragraph IV certification to the NDA holder.
- Hatch-Waxman litigation within 45 days of notice.
- A 30-month stay of ANDA approval, where applicable.
- Final FDA approval.
- Commercial launch, including authorized-generic arrangements.
- Settlement terms governing launch timing.
Patent litigation can affect entry even when the generic product has been approved. A settlement may permit launch before the latest asserted patent expiration date, subject to contractual restrictions and antitrust review.
What generic entry risks exist for Lo Loestrin Fe?
Generic entry creates three distinct risks:
Price erosion
The first generic entrant often receives a temporary market-share advantage, particularly if it obtains 180-day exclusivity after a first Paragraph IV filing. Subsequent entrants generally accelerate price competition and reduce the branded product's net price.
Volume migration
Pharmacy benefit managers, insurers, and retail pharmacies can substitute an AB-rated generic for the branded product. The substitution rate depends on state law, prescriber instructions, formulary placement, patient preference, and whether the generic matches the product's precise regimen and presentation.
Contracting pressure
Even before broad generic substitution, payers can use the prospect of entry to demand higher rebates or lower net prices. Lo Loestrin Fe's commercial defense depends on retaining favorable formulary status and demonstrating patient or prescriber value from its ultra-low-dose regimen.
The product may retain a branded niche if patients prefer its specific bleeding profile, packaging, tolerability, or physician-directed regimen. Those factors slow but do not eliminate generic erosion.
How strong is the Lo Loestrin Fe patent estate?
The patent estate is commercially weaker than an estate built around a new molecular entity because:
- The product is a mature small molecule.
- Regulatory exclusivity has expired.
- Hormonal contraceptive formulations are technically familiar to generic manufacturers.
- Substitution is established in the oral contraceptive market.
- Generic development does not require the clinical program needed for a new drug.
The estate can still be valuable if it contains enforceable claims directed to the precise low-dose formulation, tablet sequence, or product presentation. Its practical strength depends on claim scope, patent-term adjustment, prosecution history, prior art, and the availability of non-infringing generic designs.
Manufacturing patents may provide incremental protection but are less reliable than product patents as a market barrier. A generic applicant can sometimes design around process claims while maintaining pharmaceutical equivalence.
What is the financial trajectory for Lo Loestrin Fe?
AbbVie does not report Lo Loestrin Fe as a standalone revenue line in its current primary product disclosures. The product is generally included within broader women's health, established pharmaceutical, or other product categories. This prevents a reliable public calculation of annual sales, gross margin, or operating profit for the brand.
Financial trajectory by period
| Period |
Financial interpretation |
| 2010-2015 |
Commercial buildout following FDA approval and physician adoption |
| 2016-2019 |
Mature branded growth supported by low-dose positioning and contraceptive demand |
| 2020 |
Ownership transferred to AbbVie through the Allergan acquisition |
| 2021-2023 |
Mature-brand monetization with limited standalone disclosure |
| 2024 onward |
Increasing generic, pricing, and payer pressure; continued value from brand retention |
The Allergan transaction expanded AbbVie's women's health and established-brand portfolio. Lo Loestrin Fe was not the central asset in the transaction, but it contributed recurring branded pharmaceutical revenue and commercial scale. [3]
The product's likely financial pattern is a mature-brand curve: relatively stable prescription demand, declining net price as payer pressure increases, and a step-down in revenue after meaningful generic substitution. The magnitude of the decline depends more on generic launch timing and the number of approved competitors than on patient demand alone.
What commercial factors support Lo Loestrin Fe revenue?
Four factors support continued branded revenue:
- The 10-microgram estrogen dose gives physicians a clear product attribute.
- The product has more than a decade of prescribing history.
- Oral contraceptives have recurring monthly demand and high patient volume.
- Brand continuity can matter for patients who have stabilized on a specific regimen.
The main constraints are different:
- Generic alternatives are familiar to prescribers.
- Contraceptives are heavily managed by payers.
- Patients can switch among many oral and non-oral methods.
- Public policy and reimbursement changes can alter out-of-pocket costs.
- The product has no biologic manufacturing barrier and no specialty distribution requirement.
The FDA's approval of over-the-counter Opill, a progestin-only oral contraceptive, expands consumer access to contraception but does not directly substitute for Lo Loestrin Fe's combined hormonal regimen. It may increase category awareness while shifting some patients away from prescription oral contraceptives. [4]
What licensing deals affect Lo Loestrin Fe?
The principal ownership event is AbbVie's acquisition of Allergan in 2020. The transaction transferred Allergan's commercial portfolio, including Lo Loestrin Fe, to AbbVie. [3]
No separate major licensing transaction is required to explain the current U.S. ownership structure. Generic manufacturers may pursue licensing, authorized-generic, or supply arrangements, but those agreements are often confidential and should not be inferred from ordinary generic distribution relationships.
What litigation and settlement issues affect Lo Loestrin Fe?
The key litigation risk is Hatch-Waxman litigation involving Paragraph IV certifications. A court case can determine whether a generic applicant may launch before the asserted patent expiration date. Potential outcomes include:
- Patent upheld and infringed.
- Patent invalidated.
- No infringement.
- Settlement with an agreed launch date.
- Launch after expiration without litigation.
- At-risk launch followed by damages exposure.
The commercial impact is asymmetric. A first entrant can capture substantial share before additional generics arrive, while the brand owner can lose pricing power even if it preserves some volume.
How does Lo Loestrin Fe compare with other AbbVie mature brands?
Lo Loestrin Fe has a different risk profile from AbbVie's specialty and biologic assets.
| Attribute |
Lo Loestrin Fe |
AbbVie biologic or specialty brands |
| Product type |
Small-molecule combination tablet |
Often biologic or specialty small molecule |
| FDA follow-on pathway |
ANDA |
Biosimilar or specialty regulatory pathway |
| Manufacturing barrier |
Moderate |
Often high |
| Prescriber switching |
Relatively easy |
Often more controlled |
| Payer substitution |
High potential |
Usually more restricted |
| Revenue concentration risk |
Mature-brand erosion |
Patent cliffs, biologic competition, or specialty competition |
Lo Loestrin Fe contributes diversification but does not have the strategic financial scale of AbbVie's leading immunology, aesthetics, neuroscience, or oncology products.
Key Takeaways
- Lo Loestrin Fe is a mature branded oral contraceptive containing norethindrone acetate and 10 micrograms of ethinyl estradiol.
- AbbVie owns the U.S. business through its acquisition of Allergan in 2020.
- FDA regulatory exclusivity is no longer the principal protection.
- Current commercial protection depends on Orange Book-listed patents, litigation outcomes, payer contracts, and brand loyalty.
- Biosimilar risk is irrelevant because Lo Loestrin Fe is a small molecule.
- Generic entry is the primary long-term revenue risk.
- AbbVie does not separately disclose current Lo Loestrin Fe sales, so product-level revenue and margin estimates cannot be verified from public filings.
- The product retains commercial differentiation through its ultra-low-dose regimen but competes in a price-sensitive, substitution-prone market.
FAQs
Is Lo Loestrin Fe still under patent protection?
Its current protection must be determined from the live FDA Orange Book record and applicable patent litigation. Regulatory exclusivity has expired, making any remaining listed patents the relevant legal barrier.
Is there a generic version of Lo Loestrin Fe?
Generic competition is the principal risk, but approval, launch, and substitution status depend on current FDA ANDA records, patent certifications, and any settlement restrictions.
Does Lo Loestrin Fe have biosimilar competition?
No. Biosimilars apply to biologic products. Lo Loestrin Fe is a small-molecule oral contraceptive and is subject to the ANDA generic pathway.
Who manufactures Lo Loestrin Fe?
AbbVie owns the commercial business following its acquisition of Allergan. Manufacturing and distribution arrangements may involve affiliated or contract facilities.
Is Lo Loestrin Fe more commercially protected than Loestrin 24 Fe?
Its commercial differentiation is stronger than its regulatory exclusivity. The 10-microgram estrogen formulation and brand recognition distinguish it from many alternatives, but those factors do not prevent generic substitution if an equivalent generic reaches the market.
References
-
U.S. Food and Drug Administration. (2024). Lo Loestrin Fe prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
AbbVie Inc. (2020). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. AbbVie.
-
U.S. Food and Drug Administration. (2023). FDA approves first nonprescription daily oral contraceptive. FDA.
